Navigation Links
Discovery at JGH opens door to new treatments for prostate, brain and skin cancers
Date:1/7/2010

This release is available in French.

Researchers at the Lady Davis Institute for Medical Research of the Jewish General Hospital and McGill University in Montreal have discovered a previously unsuspected link between two different genetic pathways which suppress the growth of cancer tumours. This breakthrough, they say, could lead to new treatments for some of the deadliest and most intractable forms of cancer; including prostate cancer, brain cancer and melanoma.

The scientists discovered a novel link between a tumour-suppressing gene known as the phosphatase and tensin homolog (PTEN) and a protein called PKR, which is known to inhibit protein synthesis. The researchers discovered that when PTEN is mutated or absent, PKR loses its inhibitory ability, and protein synthesis within the affected cells runs wild.

"This leads to high proliferation of cells with a survival advantage over normal cells," explains Dr. Antonis E. Koromilas of the JGH Lady Davis Institute for Medical Research and McGill's Department of Oncology. "That is a condition that facilitates tumour development."

PTEN plays a vital role in the suppression of humans cancers by inhibiting a genetic pathway called phosphoinositide-3 kinase (PI3K). Clinicians often target PI3K with drugs when treating cancer patients, but this does not work in all cases, because not all mutant forms of PTEN interact with PI3K. In 1992, in a study published in the journal Science, Dr. Koromilas and Dr. Nahum Sonenberg of McGill University identified PKR as a potential tumour suppressor, but its association with PTEN was unsuspected at the time.

The new discovery was made by Koromilas's graduate researcher Zineb Mounir, the study's first author, along with colleagues in the United States. Their findings were published December 22 in the journal Science Signalling.

'/>"/>
Contact: Mark Shainblum
mshainblum@jgh.mcgill.ca
514-340-8222 x6592
Jewish General Hospital
Source:Eurekalert

Page: 1 2

Related biology news :

1. Discovery of a new molecular mechanism that guides visual nerves towards the brain
2. New discovery by Harvard scientists aims to correct cellular defects leading to diabetes
3. New year, new vitamin C discovery: It cures mice with accelerated aging disease
4. Emerald BioStructures announces discovery of small molecule modulators of PDE4
5. UGA researchers lead team in discovery involving devastating freshwater fish parasite, Ich
6. Discovery makes brain tumor cells more responsive to radiation
7. Discovery of the Jekyll-and-Hyde factors in coral bleaching
8. Rocket science leads to new whale discovery
9. A year after discovery, Congos mother lode of gorillas remains vulnerable
10. Cancer metabolism discovery uncovers new role of IDH1 gene mutation in brain cancer
11. Its a gas: New discovery may lead to heartier, high-yielding plants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/14/2015)... 14, 2015  HYPR Corp. today announced it ... ) Alliance tm , an industry consortium transforming ... to share technology and collaborate to deliver open ... more secure and private, and easier to use. ... that protects sensitive user information and eliminates the ...
(Date:4/13/2015)... 2015 According to a ... Market Forecast & Opportunities, 2020", the global biometrics market ... 14% till 2020. The biometrics market is garnering ... and review of biometric management systems. The constant ... with greater efficiency, are resulting in increasing installation ...
(Date:4/10/2015)... DUBLIN , April 10, 2015 ... the addition of the "Security Competitive Profiles - ... (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , NEC will continue to ... solutions to the market, with a company focus on ... solution anticipated. Winning opportunities in the ...
Breaking Biology News(10 mins):HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2NEC Security Competitive Profile 2015 2
... Hopkins University researchers have created biodegradable nanosized particles ... and viscous mucus secretions to deliver a sustained-release ... nanoparticles, which degrade over time into harmless components, ... suffering from dozens of health conditions, including diseases ...
... the likely origin of the Devil Facial Tumour Disease (DFTD) ... team of scientists has discovered. Devil Facial Tumour ... devils and was first reported in 1996. It is spread ... characterised by large tumours, mostly on the face and mouth, ...
... chemical modification on an important muscle protein, a University of ... potentially lead to new treatments for the conditions. ... of the journal Science , may also have implications ... initially made, most proteins are modified through the addition of ...
Cached Biology News:Biodegradable particles can bypass mucus, release drugs over time 2Biodegradable particles can bypass mucus, release drugs over time 3Nervous culprit found for Tassie devil facial tumor disease 2Unusual protein modification involved in muscular dystrophy, cancer 2
(Date:5/28/2015)... Glenn Keet, CEO of Clinovo , ... Clinical Data Integration with EDC Systems ” at the ... on June 14th-18th. , During the presentation, Glenn Keet ... EDC, and will examine the value of patient engagement, ... health records/electronic medical records integration. , The presentation ...
(Date:5/28/2015)... Dr. Carl Peck, MD, Chairman ... L. Williams, MD, has joined the firm as ... are top tier consultants whose expertise and professional ... the company’s clients. Premier Experts collaborate to design ... develop their medical products, pursue optimal regulatory pathways, ...
(Date:5/27/2015)... May 27, 2015 RXi Pharmaceuticals Corporation ... on discovering and developing innovative therapies primarily in ... it has commenced a public offering of shares ... of its common stock and overallotment purchase rights ... shares of common stock, warrants and overallotment purchase ...
(Date:5/27/2015)... 2015 Expanding in a big way ... Avalon Biomed Inc. recently inked a deal with ... Co. Ltd. , the largest endodontic distributor in Japan. ... market for Avalon Biomed, which manufactures Grey MTA Plus® ... dental cements that have won renown from dentists around ...
Breaking Biology Technology:Clinovo Presents at the DIA 2015 51st Annual Meeting in Washington, DC on June 14th-18th 2Former CEO and Chair of the Council of Experts at the USP, Roger L. Williams, MD, Joins NDA Partners as a Premier Expert Consultant 2RXi Pharmaceuticals Announces Proposed Public Offering of Common Stock and Warrants 2RXi Pharmaceuticals Announces Proposed Public Offering of Common Stock and Warrants 3Dental Manufacturer Avalon Biomed Inks Major Deal with Japanese Distributor 2Dental Manufacturer Avalon Biomed Inks Major Deal with Japanese Distributor 3
... Reportlinker.com announces that a new market research report ... Global Marine Biotechnology Industry ... analyzes the Global markets for Marine Biotechnology in ... Biomaterials, Marine Bioactive Substances, and Others. The Major ...
... MYL ) today announced its financial results for the three and ... for 2011.   Financial Results ... 2010 compared to $0.33 for the same prior year quarter, an ... the year ended December 31, 2010 compared to $1.30 for the ...
... Feb. 24, 2011 Quest Diagnostics Incorporated (NYSE: ... testing, information and services, announced today that it has ... esoteric laboratory specializing in genetic testing for neurological disorders, ... for $740 million in cash.   Athena ...
Cached Biology Technology:Reportlinker Adds Global Marine Biotechnology Industry 2Mylan Reports Adjusted Diluted EPS of $0.45 for the Quarter, a 36% Increase over Prior Year Quarter; and $1.61 for the Year, a 24% Increase over Prior Year 2Mylan Reports Adjusted Diluted EPS of $0.45 for the Quarter, a 36% Increase over Prior Year Quarter; and $1.61 for the Year, a 24% Increase over Prior Year 3Mylan Reports Adjusted Diluted EPS of $0.45 for the Quarter, a 36% Increase over Prior Year Quarter; and $1.61 for the Year, a 24% Increase over Prior Year 4Mylan Reports Adjusted Diluted EPS of $0.45 for the Quarter, a 36% Increase over Prior Year Quarter; and $1.61 for the Year, a 24% Increase over Prior Year 5Mylan Reports Adjusted Diluted EPS of $0.45 for the Quarter, a 36% Increase over Prior Year Quarter; and $1.61 for the Year, a 24% Increase over Prior Year 6Mylan Reports Adjusted Diluted EPS of $0.45 for the Quarter, a 36% Increase over Prior Year Quarter; and $1.61 for the Year, a 24% Increase over Prior Year 7Mylan Reports Adjusted Diluted EPS of $0.45 for the Quarter, a 36% Increase over Prior Year Quarter; and $1.61 for the Year, a 24% Increase over Prior Year 8Mylan Reports Adjusted Diluted EPS of $0.45 for the Quarter, a 36% Increase over Prior Year Quarter; and $1.61 for the Year, a 24% Increase over Prior Year 9Mylan Reports Adjusted Diluted EPS of $0.45 for the Quarter, a 36% Increase over Prior Year Quarter; and $1.61 for the Year, a 24% Increase over Prior Year 10Mylan Reports Adjusted Diluted EPS of $0.45 for the Quarter, a 36% Increase over Prior Year Quarter; and $1.61 for the Year, a 24% Increase over Prior Year 11Mylan Reports Adjusted Diluted EPS of $0.45 for the Quarter, a 36% Increase over Prior Year Quarter; and $1.61 for the Year, a 24% Increase over Prior Year 12Mylan Reports Adjusted Diluted EPS of $0.45 for the Quarter, a 36% Increase over Prior Year Quarter; and $1.61 for the Year, a 24% Increase over Prior Year 13Mylan Reports Adjusted Diluted EPS of $0.45 for the Quarter, a 36% Increase over Prior Year Quarter; and $1.61 for the Year, a 24% Increase over Prior Year 14Mylan Reports Adjusted Diluted EPS of $0.45 for the Quarter, a 36% Increase over Prior Year Quarter; and $1.61 for the Year, a 24% Increase over Prior Year 15Mylan Reports Adjusted Diluted EPS of $0.45 for the Quarter, a 36% Increase over Prior Year Quarter; and $1.61 for the Year, a 24% Increase over Prior Year 16Mylan Reports Adjusted Diluted EPS of $0.45 for the Quarter, a 36% Increase over Prior Year Quarter; and $1.61 for the Year, a 24% Increase over Prior Year 17Mylan Reports Adjusted Diluted EPS of $0.45 for the Quarter, a 36% Increase over Prior Year Quarter; and $1.61 for the Year, a 24% Increase over Prior Year 18Quest Diagnostics to Acquire Athena Diagnostics, Establishing Leading Position in Rapidly Growing Neurology Testing Market 2Quest Diagnostics to Acquire Athena Diagnostics, Establishing Leading Position in Rapidly Growing Neurology Testing Market 3Quest Diagnostics to Acquire Athena Diagnostics, Establishing Leading Position in Rapidly Growing Neurology Testing Market 4
Alpha-2-antiplasmin precursor (Alpha-2-plasmin inhibitor) (Alpha-2-PI) (Alpha-2-AP). [Source:Uniprot/SWISSPROT;Acc:P08697] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
... to HDAC8 Regulation of gene ... such as DNA methylation, ATP-dependent chromatin ... histones, which include the dynamic acetylation ... lysine residues present in the tail ...
Mouse monoclonal antibody raised against a partial recombinant AAAS. NCBI Entrez Gene ID = AAAS...
... Deletion Cosmid Cloning Kit enables you to ... and unbiased primary cosmid library of genomic ... deletion sublibraries. High efficiency cosmid library construction ... kit protocols. First, genomic DNA is randomly ...
Biology Products: